Pharmaceuticals - Indian - Bulk Drugs
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,787.05 | 2,028.44 | 1,947.61 | 1,725.42 | 1,510.96 |
Total Expenses | 1,691.55 | 1,923.08 | 1,729.05 | 1,518.99 | 1,368.98 |
Profit Before Tax | 95.50 | 105.36 | 218.56 | 206.43 | 126.58 |
Profit After Tax | 69.60 | 78.38 | 160.50 | 133.14 | 84.44 |
Operating Profit after Depreciation | 151.87 | 153.47 | 249.78 | 242.62 | 194.40 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,070.63 | 958.39 | 889.07 | 721.40 | 743.93 |
Total Non Current Assets | 1,520.53 | 1,446.46 | 1,248.83 | 1,034.62 | 993.22 |
Total Current Assets | 966.62 | 939.02 | 964.28 | 878.60 | 774.76 |
TOTAL ASSETS | 2,487.15 | 2,385.48 | 2,213.11 | 1,913.22 | 1,767.98 |
Total Shareholder's Fund | 1,187.66 | 1,133.47 | 1,067.98 | 933.40 | 816.50 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 186.72 | 315.31 | 293.73 | 229.02 | 284.93 |
Net Cash used in Investing Activities | -173.75 | -292.34 | -284.37 | -156.20 | -163.80 |
Net Cash used in Financing Activities | -27 | -7.68 | -5.56 | -96.87 | -100.86 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,787.05 | 2,028.44 | 1,947.61 | 1,725.42 | 1,510.96 |
Total Expenses | 1,691.63 | 1,923.08 | 1,729.04 | 1,518.99 | 1,368.98 |
Profit Before Tax | 95.41 | 105.36 | 218.57 | 206.43 | 126.58 |
Profit After Tax | 69.51 | 78.38 | 160.51 | 133.14 | 84.44 |
Operating Profit after Depreciation | 151.78 | 153.46 | 249.79 | 242.62 | 194.40 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,070.63 | 958.39 | 889.07 | 721.40 | 743.93 |
Total Non Current Assets | 1,520.54 | 1,446.47 | 1,248.84 | 1,034.63 | 993.23 |
Total Current Assets | 966.53 | 939 | 964.28 | 878.60 | 774.76 |
TOTAL ASSETS | 2,487.07 | 2,385.48 | 2,213.12 | 1,913.23 | 1,767.99 |
Total Shareholder's Fund | 1,187.59 | 1,133.49 | 1,068.01 | 933.42 | 816.52 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 186.62 | 315.29 | 293.73 | 229.02 | 284.93 |
Net Cash used in Investing Activities | -173.75 | -292.34 | -284.37 | -156.20 | -163.80 |
Net Cash used in Financing Activities | -27 | -7.68 | -5.56 | -96.87 | -100.86 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 452.90 | 406.80 | 514.20 | 447.57 | 434.88 |
Total Expenses | 378 | 348.80 | 419.80 | 382.81 | 377.36 |
Profit Before Tax | 24.80 | 6.90 | 47.30 | 21.61 | 16.86 |
Profit After Tax | 18.30 | 5.10 | 33.90 | 16.14 | 12.57 |
Operating Profit after Depreciation | 75.30 | 58.50 | 94.90 | 64.82 | 58.51 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 452.90 | 406.80 | 514.20 | 447.57 | 434.90 |
Total Expenses | 378.20 | 348.70 | 419.80 | 382.68 | 377.40 |
Profit Before Tax | 24.60 | 7 | 47.30 | 21.74 | 16.80 |
Profit After Tax | 18.10 | 5.20 | 33.90 | 16.27 | 12.50 |
Operating Profit after Depreciation | 75.10 | 58.60 | 94.90 | 64.95 | 58.50 |
₹0.6/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Hikal Ltd | ₹372.80 | ₹4,596.65 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
26 Dec 2024, 12:34 pm
06 Nov 2024, 06:12 pm
23 Aug 2024, 09:10 pm
22 Jul 2024, 05:44 pm
10 May 2024, 11:53 am